Increase patient treatment compliance by eliminating injection pain and associated apprehension.

The GentleDispense System uses a low power-activated, needle-free patch for transdermal delivery of large molecule compounds. Designed for flexible use – either plug-in or battery use.

Key Results
- Delivered Enfuvirtide/T-20 (M.W. 4492 Da).
- 25 to 30% delivery rate compared to 0% with passive patch.
- Produced negligible tissue damage in chronic porcine study.
- The passive patch contained T-20 and was applied long-term (for 12 hours).
- The active patch was applied (for 30 minutes) over the passive patch to help the drug permeate the skin.

Potential Delivery Uses
- Drugs
- Peptides
- Hydration
- Nutrition

Other compounds too large for passive transport through the skin

Negligible Skin Damage.

Successful Delivery of Large Molecule Drug.

Porcine study with the GentleDispense System 30-day, twice daily saline treatment evaluated skin health via histology and transepidermal water loss (TEWL). Histology showed little to no inflammation. TEWL values well within healthy range of less than 25 g/m²/h.

30-day porcine study using the GentleDispense System and injection twice daily treatments compared bioavailability between delivery methods for T-20 (M.W. 4492 Da). Long-term bioavailability (C(₉₅₆₄)ₚ) of T-20 using GentleDispense near clinical levels for T-20 using same dose as injection.

These works were partially supported by the National Institutes of Health Small Business Innovation Research (SBIR) grant No. R44AI08335. The views, opinions and/or findings contained in this work are those of Actuated Medical, Inc. and should not be construed as an official government position, policy or decision unless so designated by other documentation.

Pending 510(k), not available for sale within the United States.